Welcome to our dedicated page for Antibe Therapeut news (Ticker: ATBPF), a resource for investors and traders seeking the latest updates and insights on Antibe Therapeut stock.
Antibe Therapeutics Inc. (ATBPF) is a clinical-stage biotechnology company advancing novel therapies for pain and inflammation. This page aggregates official announcements, research milestones, and financial disclosures to serve as a comprehensive resource for stakeholders.
Access timely updates on clinical trial progress, regulatory developments, and strategic partnerships that shape the company's trajectory. Our curated feed includes earnings reports, patent filings, and scientific presentations - all essential for understanding Antibe's position in the competitive biotech landscape.
Key focus areas include updates on lead drug candidates, collaborations with research institutions, and analyses presented at medical conferences. The collection prioritizes material events that influence therapeutic development timelines and commercial potential assessments.
Bookmark this page for streamlined access to Antibe's verified corporate communications. For real-time alerts on new developments, consider subscribing to Stock Titan's regulatory update service.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in the Precision in Clinical Trials Summit in Boston on May 1-2, 2023. Chief Medical Officer Dr. Joseph Stauffer will present Antibe’s clinical program for otenaproxesul, a drug designed to provide safer pain relief alternatives to opioids and NSAIDs, particularly addressing gastrointestinal side effects. Antibe's pipeline includes ATB-352, targeting specialized pain indications and aims to develop new therapies for inflammatory bowel disease. This summit offers a platform for clinical trial professionals to discuss innovations in the field.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) has announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023. The Company, focused on developing safer therapies for inflammation using its hydrogen sulfide platform, will present on April 26, 2023, at 1:30 pm ET at the Metro Toronto Convention Centre.
Chief Operating Officer Scott Curtis and Chief Medical Officer Dr. Joseph Stauffer will lead the presentation. A webcast link is available on the Company’s website and will remain accessible for 90 days. The conference aims to connect investors with developments from various companies in the Canadian healthcare sector.
Antibe's pipeline includes drugs targeting GI issues from NSAIDs and alternatives for opioids. Learn more at antibethera.com.
FAQ
What is the market cap of Antibe Therapeut (ATBPF)?
